Daniel Jeffries

1 presentation

• AB-300, A NOVEL 5-HT2A/2C AGONIST, REVERSES MOTIVATIONAL DEFICITS IN A TETRABENAZINE MODEL OF PARKINSON’S DISEASE APATHY

  2026 ASCP Annual Meeting